RNS & Investor News

2024

Notice of Results

13 May 2015

Analyst Briefing

OptiBiotix Health Plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its results for the year ended 30 November 2014 on Friday 29 May 2015.

A briefing for analysts will take place at Walbrook PR, 4 Lombard Street, London EC3V 9HD at 9.30am on Friday 29 May 2015.

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP
Claire Louise Noyce
Tel: 020 3713 4581
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

2023

Notice of Results

13 May 2015

Analyst Briefing

OptiBiotix Health Plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its results for the year ended 30 November 2014 on Friday 29 May 2015.

A briefing for analysts will take place at Walbrook PR, 4 Lombard Street, London EC3V 9HD at 9.30am on Friday 29 May 2015.

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP
Claire Louise Noyce
Tel: 020 3713 4581
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

2022

Notice of Results

13 May 2015

Analyst Briefing

OptiBiotix Health Plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its results for the year ended 30 November 2014 on Friday 29 May 2015.

A briefing for analysts will take place at Walbrook PR, 4 Lombard Street, London EC3V 9HD at 9.30am on Friday 29 May 2015.

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP
Claire Louise Noyce
Tel: 020 3713 4581
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

2021

Notice of Results

13 May 2015

Analyst Briefing

OptiBiotix Health Plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its results for the year ended 30 November 2014 on Friday 29 May 2015.

A briefing for analysts will take place at Walbrook PR, 4 Lombard Street, London EC3V 9HD at 9.30am on Friday 29 May 2015.

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP
Claire Louise Noyce
Tel: 020 3713 4581
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

2020

Notice of Results

13 May 2015

Analyst Briefing

OptiBiotix Health Plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its results for the year ended 30 November 2014 on Friday 29 May 2015.

A briefing for analysts will take place at Walbrook PR, 4 Lombard Street, London EC3V 9HD at 9.30am on Friday 29 May 2015.

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP
Claire Louise Noyce
Tel: 020 3713 4581
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

2019

Notice of Results

13 May 2015

Analyst Briefing

OptiBiotix Health Plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its results for the year ended 30 November 2014 on Friday 29 May 2015.

A briefing for analysts will take place at Walbrook PR, 4 Lombard Street, London EC3V 9HD at 9.30am on Friday 29 May 2015.

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP
Claire Louise Noyce
Tel: 020 3713 4581
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

2018

Notice of Results

13 May 2015

Analyst Briefing

OptiBiotix Health Plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its results for the year ended 30 November 2014 on Friday 29 May 2015.

A briefing for analysts will take place at Walbrook PR, 4 Lombard Street, London EC3V 9HD at 9.30am on Friday 29 May 2015.

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP
Claire Louise Noyce
Tel: 020 3713 4581
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

2017

Notice of Results

13 May 2015

Analyst Briefing

OptiBiotix Health Plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its results for the year ended 30 November 2014 on Friday 29 May 2015.

A briefing for analysts will take place at Walbrook PR, 4 Lombard Street, London EC3V 9HD at 9.30am on Friday 29 May 2015.

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP
Claire Louise Noyce
Tel: 020 3713 4581
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

2016

Notice of Results

13 May 2015

Analyst Briefing

OptiBiotix Health Plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its results for the year ended 30 November 2014 on Friday 29 May 2015.

A briefing for analysts will take place at Walbrook PR, 4 Lombard Street, London EC3V 9HD at 9.30am on Friday 29 May 2015.

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP
Claire Louise Noyce
Tel: 020 3713 4581
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

2015

Notice of Results

13 May 2015

Analyst Briefing

OptiBiotix Health Plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its results for the year ended 30 November 2014 on Friday 29 May 2015.

A briefing for analysts will take place at Walbrook PR, 4 Lombard Street, London EC3V 9HD at 9.30am on Friday 29 May 2015.

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP
Claire Louise Noyce
Tel: 020 3713 4581
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

2014

Notice of Results

13 May 2015

Analyst Briefing

OptiBiotix Health Plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its results for the year ended 30 November 2014 on Friday 29 May 2015.

A briefing for analysts will take place at Walbrook PR, 4 Lombard Street, London EC3V 9HD at 9.30am on Friday 29 May 2015.

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP
Claire Louise Noyce
Tel: 020 3713 4581
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002

 

2013

Notice of Results

13 May 2015

Analyst Briefing

OptiBiotix Health Plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its results for the year ended 30 November 2014 on Friday 29 May 2015.

A briefing for analysts will take place at Walbrook PR, 4 Lombard Street, London EC3V 9HD at 9.30am on Friday 29 May 2015.

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP
Claire Louise Noyce
Tel: 020 3713 4581
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002